Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results
Rhea-AI Summary
Positive
- None.
Negative
- None.
Market reaction after 3Q26 earnings report: EMBC +10.86%
Following this news, EMBC has gained 10.86%, reflecting a significant positive market reaction. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.88.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | 2Q26 earnings | Negative | -57.8% | Quarterly results announcement was followed by a 57.84% negative 24-hour reaction. |
| Feb 05 | 1Q26 earnings | Neutral | -7.8% | Results announcement contained no quantified operating results, followed by a 7.75% decline. |
| Nov 25 | FY25 earnings | Negative | -7.2% | Revenue pressure and initial fiscal 2026 guidance preceded a 7.24% negative reaction. |
| Aug 08 | 3Q25 earnings | Positive | +18.5% | Strong revenue, earnings and guidance results preceded an 18.53% positive reaction. |
| May 09 | 2Q25 earnings | Negative | -10.0% | Revenue decline and lowered revenue guidance preceded a 10.00% negative reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of five tag-matched earnings events had negative 24-hour reactions; the average move was -12.86%, while Q3 fiscal 2025 was positive.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported third quarter fiscal 2026 financial results.
Visit the company’s Investor Relations website at http://investors.embecta.com to view the detailed third quarter fiscal 2026 earnings press release and investor presentation.
The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, Aug 7, 2026, which is accessible here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com.
A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 7, 2026, via the embecta investor relations website and archived on the website for one year.
About embecta
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
Contacts:
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| Contact Media Relations | Contact IR |
